



# Efficacy and safety of *Coccinia grandis* (L.) Voigt on blood glucose and lipid profile: An updated systematic review and meta-analysis

Wiraphol Phimarn<sup>1\*</sup>, Chatmanee Taengthonglang<sup>2</sup>, Bunleu Sungthong<sup>3</sup><sup>1</sup>Social Pharmacy Research Unit, Faculty of Pharmacy, Mahasarakham University, Kantharawichai, Maha Sarakham, Thailand, 44150<sup>2</sup>Pharmacy department, Surin Hospital, Surin, Thailand, 32000<sup>3</sup>Integrative Pharmaceuticals and Innovative of Pharmaceutical Technology Research Unit, Faculty of Pharmacy, Mahasarakham University, Khamriang, Kantharawichai, Maha Sarakham, Thailand, 44150

## ARTICLE INFO

**Article Type:**  
Review**Article History:**  
Received: 26 October 2023  
Accepted: 31 May 2024**Keywords:**  
*Coccinia grandis*  
Lipid profiles  
Blood glucose  
Dyslipidemias  
Meta-analysis  
Systematic review

## ABSTRACT

**Introduction:** *Coccinia grandis* has been shown to improve blood glucose and lipids. The results of earlier clinical studies on the effects of *C. grandis* on blood sugar and lipid profile are debatable. This meta-analysis aimed to evaluate, using randomized controlled trials (RCTs), the effects of consuming *C. grandis* on lipid profiles and blood glucose levels.**Methods:** Thai and English articles by two independent authors were searched in PubMed, ScienceDirect, Scopus, and ThaiJo up to November 2023 for a systematic review. The keywords were developed based on MeSH terms as follows: (*Coccinia grandis* OR *Coccinia cordifolia* OR *Coccinia indica*) AND (fasting blood glucose OR FBS OR fasting plasma glucose OR FPG OR HbA1C OR postprandial glucose OR PPG OR lipid profile OR low-density lipoprotein OR LDL OR high-density lipoprotein OR HDL OR total cholesterol OR TC OR triglyceride OR TG). The Laird and DerSimonian random-effect model was used to pool the findings. Seven trials with 595 individuals and 1–90-day treatments were included.**Results:** The combined data revealed a noteworthy decline in fasting blood sugar (FBS); standardized mean difference (SMD) by -1.99 mg/dL ( $P<0.001$ ), 1-hour postprandial glucose (PPG) by -0.99 mg/dL ( $P<0.001$ ), 2-hour PPG by -0.69 mg/dL ( $P=0.004$ ) and triglycerides (TG) by -0.46 mg/dL ( $P=0.001$ ). However, there were no significant differences in hemoglobin A1C (HbA1C), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and total cholesterol (TC). No major intervention side effects were recorded.**Conclusion:** Our investigation found that *C. grandis* reduced FBS, PPG, and TG. The treatment's long-term advantages and safety are unknown.

### Implication for health policy/practice/research/medical education:

This meta-analysis indicates that the consumption of *Coccinia grandis* has the potential to reduce FBS, PPG, and TG. This therapeutic modality is an adjunctive therapy for patients diagnosed with diabetes mellitus and hyperlipidemia.**Please cite this paper as:** Phimarn W, Taengthonglang C, Sungthong B. Efficacy and safety of *Coccinia grandis* (L.) Voigt on blood glucose and lipid profile: An updated systematic review and meta-analysis. J Herbmed Pharmacol. 2024;13(3):342-352. doi: 10.34172/jhp.2024.49331.

## Introduction

Cardiometabolic risk factors represent a paramount global cause of mortality, exerting a profound and pervasive impact annually (1,2). Moreover, empirical data substantiates the disconcerting reality that over 60% of fatalities stemming from diverse chronic ailments can be attributed to the pernicious influence of cardiovascular risk factors (3). Cardiometabolic risk factors significantly

burden the healthcare system (4).

Previous studies have consistently shown a relationship between elevated blood glucose, hemoglobin A1C (HbA1C), and postprandial plasma glucose (PPG) levels and the morbidity of cardiovascular disease (CVD) (5). Furthermore, the increased levels of triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) increase the risk of CVD, but

\*Corresponding author: Wiraphol Phimarn,  
Email: wiraphol.p@msu.ac.th

high-density lipoprotein cholesterol (HDL-C) provides protection (6,7). Another study has demonstrated that attempts to lower blood glucose levels effectively decreased cardiovascular problems (8). Furthermore, the incidence of ischemic heart disease among participants decreased by 12%–20% throughout the five-year follow-up when LDL levels were reduced by about 10% (9).

These risk factors are intimately linked with impaired glucose metabolism, insulin resistance, and dyslipidemia, which significantly elevate the risk of various chronic ailments, including diabetes, obesity, hepatic steatosis, and CVDs (10). Managing blood glucose and lipid profiles can be achieved through the adoption of appropriate dietary patterns, serving as preventive or control measure for diabetes and related conditions (11). Intriguingly, the realm of non-pharmacological strategies, encompassing health-focused diets and functional foods, such as herbal medicine, has garnered considerable attention as providing valuable approaches in addressing these challenges (12,13).

*Coccinia grandis* (L.) Voigt, a perennial climber belonging to the Cucurbitaceae family, is indigenous to tropical regions of Asia, notably prevalent in Thailand, Sri Lanka, India, and Pakistan. The leaf extract of *C. grandis* holds a venerable position in Ayurvedic medicine as an adjunctive therapy for the management of diabetes mellitus (14). Beyond this, the plant's leaves are recognized for their multifaceted therapeutic properties, encompassing antioxidative and anti-inflammatory attributes (15,16). In streptozotocin-induced diabetic rats and normoglycemic rats, Attanayake's study has examined the acute hypoglycemia potential of an alcoholic extract of *C. grandis* (17). Likewise, methanolic leaf extract's impact on lipid profiles and liver enzymes in streptozotocin-induced diabetic rats has been investigated (18). Moreover, in rats with diabetes induced by alloxan, there have been reports of *C. grandis* aqueous leaf extract's hypolipidemic properties.

Initial investigations have determined that an aqueous *C. grandis* leaf extract, given at a dose of 0.75 g/kg, constitutes an optimally effective and safe therapeutic modality, demonstrating promise as an antihyperglycemic agent in rat models (19). Multiple randomized controlled trials (RCTs) have been undertaken to assess the potential causal relationship between *C. grandis* supplementation and its impact on blood glucose levels and lipid profiles. Hence, the aim of this study was to conduct a comprehensive review of the literature regarding the effects of *C. grandis* supplementation on lipid profiles and blood glucose levels in RCTs, including diabetic patients, and to compile and update the material in a meta-analysis.

## Methods

### Search strategy

The referred Reporting Items for Systematic Reviews

and Meta-Analysis (PRISMA) guidelines were closely followed during the current inquiry, guaranteeing the methodological rigor and transparency of this evaluation (20) and the PROSPERO database has the protocol recorded (CRD42023482144). A thorough and systematic search was executed across the world's most prominent databases including PubMed, Scopus, ScienceDirect, and ThaiJo. This study was conducted up to 30 November 2023. The primary aim of this comprehensive search, conducted in both English and Thai languages, was to identify RCTs examining the impact of *Coccinia grandis* on a spectrum of pertinent clinical parameters. The results that were of particular importance included PPG, fasting blood glucose (FBG), HbA1C, and the lipid profile parameters, which included TG, TC, HDL, and LDL.

Medical Subject Headings (MeSH) was used as part of the search strategy for this investigation in order to carefully query the databases. The MeSH terms used were as follows: (*Coccinia grandis* OR *C. grandis* OR *Coccinia cordifolia* OR *C. cordifolia* OR *Coccinia indica* OR *C. indica*) AND (blood glucose OR fasting blood glucose OR FBS OR fasting plasma glucose OR FPG OR HbA1C OR postprandial glucose OR PPG OR lipid profile OR Low-density Lipoprotein OR LDL OR High-Density Lipoprotein OR HDL OR total cholesterol OR TC OR triglyceride OR TG). Furthermore, in an endeavor to ensure a comprehensive review of the pertinent literature, a thorough examination was conducted on the reference lists of the recovered and reviewed studies. This supplementary method was pursued to identify any relevant articles that might have eluded our initial search, due to various factors. Such articles were evaluated through a manual review process. It is imperative to note that the eligibility of all potential abstracts and titles was independently assessed by two reviewers, namely WP and CT, to confirm that the analysis contained only studies that met the eligibility requirements.

### Selection criteria

The present authors conducted a thorough review of the literature, independently identifying pertinent articles. Duplicate articles were eliminated through careful screening of titles, abstracts, and full-text contents. Trials were included if they met the following pre-established criteria: 1) randomized study design with participants aged 18 years or older, 2) comprehensive details on the *C. grandis* product, 3) comparative analysis between *C. grandis* and a placebo, and 4) baseline measurements, outcomes of interest, and documentation of any adverse events. To ensure the robustness of the analysis, non-randomized controlled trials and animal research were omitted. Lipid profiles and blood glucose levels were evaluated as the main outcomes of interest in this investigation. Secondary outcomes included liver and renal function tests, and potential adverse effects.

### Data extraction

Two independent reviewers (WP and CT) extracted relevant data from the full manuscripts of eligible studies into an electronic database. Extracted data included patient characteristics, study design, intervention, number of participants in each group, and outcomes. A third reviewer (BS) reconciled any disagreements. When necessary, the original authors were contacted for clarification or additional data.

### Information extraction

This meta-analysis extracted the following data from relevant studies: mean and standard deviation (SD) of primary outcomes (FBS, HbA1C, PPG, LDL, HDL, TC, and TG) before and after intervention, liver function tests, renal function tests, and the number of adverse events. The following information was also extracted: the name of the authors, the year the work was published, the country, the number of participants in the intervention and control groups, the sex, age (years), and state of the participants' health, the duration of the intervention, and the extract dosage.

### Quality measurement

Two authors independently used the Cochrane Risk of Bias Tool for Randomized Controlled Trials to assess the potential for bias in the included studies (21). This tool assesses the following domains: random sequence generation, blinding, allocation concealment, partial result data, and other potential sources of bias. The degree of bias was rated as low, high, or unclear for each domain. Any inconsistencies or differences in the information extraction or risk assessment were resolved by a third author.

### Data synthesis and statistical analysis

Statistical analysis was performed using Review Manager (RevMan®, v. 5.3; Cochrane Collaboration) and Stata software version 15.0 (StataCorp, College Station, TX, USA). Utilizing the standardized mean difference (SMD) with a 95% confidence interval (CI), the effectiveness was evaluated. Heterogeneity was examined using the Q-statistic with  $I^2$  results.  $I^2 \geq 50\%$  ( $P < 0.10$ ) indicated statistical heterogeneity. The random-effects model was used for all outcomes. To make sure robustness, the sensitivity analyses with fixed-effect models were carried out. Subgroup analyses were conducted based on the study design and treatment duration. Funnel plots were used to evaluate publication bias. Safety outcomes were descriptively reported.

### Results

Upon conducting a comprehensive screening of the available literature, the initial search across established databases yielded a total of 1256 articles, as illustrated

in Figure 1. After meticulous removal of the duplicate articles, this number was substantially reduced to 371 studies. Subsequent refinement of the selection criteria, undertaken through a judicious review of titles and abstracts, led to the exclusion of 309 articles. The remaining studies, deemed potentially pertinent, underwent further scrutiny based on a thorough examination of their full texts. Within this phase, one article was excluded as it represented a duplication. Ultimately, in alignment with the stringent criteria outlined for our investigation, a total of seven trials (22-28) met the inclusion criteria and were thus subjected to a comprehensive analysis. These seven studies collectively furnished a comprehensive evaluation of *C. grandis*' impact on blood sugar levels. Furthermore, within this cohort, three studies were identified which specifically addressed the influence of *C. grandis* on lipid profiles.

### Study characteristics

Table 1 lists the characteristics of the pooled studies. Three studies were conducted in India (22,23,26), two studies performed in Sri Lanka (24,27), one trial in Thailand (25) and one study in Australia (28). Our meta-analysis contained only RCTs. Four trials (23,24,27,28) were double blinded RCTs. The duration of studies varied from one to ninety days. Four studies (23,25,27,28) examined the effects of 500 mg/d *C. grandis* extract. Six trials were performed in DM type 2 patients (22-27) and one trial performed in prediabetes participants (28). The study participants' ages ranged from 37 to 70 years.

### Quality assessment

Considering the methods reported for generating randomization sequences, it was discerned that merely two out of the seven studies exhibited an elevated risk of bias (23,25). The remaining studies predominantly exhibited an elevated or indeterminate risk of bias, primarily attributed to concerns regarding allocation concealment and participant blinding. In terms of selective reporting, the majority of studies provided comprehensive descriptions. Based on a comprehensive evaluation, the Cochrane Handbook for Systematic Reviews of Interventions' criteria were generally met, with the included studies' quality being judged at a noteworthy level (20) (Figure 2).

### Meta-analysis

#### Blood glucose

A random-effect meta-analysis revealed a significant reduction in FBS with *C. grandis* (SMD -1.99 mg/dL; 95% CI -2.95, -1.04;  $P < 0.001$ ). Additionally, there were significant reductions in 1-hour and 2-hour PPG (SMD -0.99 mg/dL; 95% CI -1.79, -0.19;  $P < 0.001$  and SMD -0.72 mg/dL; 95% CI -0.93, -0.50;  $P = 0.004$ , respectively). However, *C. grandis* did not significantly reduce HbA1c




Figure 1. Flow diagram showing how the studies considered in this analysis were chosen

(SMD -0.71%; 95% CI -1.44, 0.01;  $P=0.05$ ). There was a significant heterogeneity in these outcomes ( $I^2 \geq 50\%$ ). The model was changed from a random effect model to a fixed effect model in a sensitivity analysis. HbA1c was significant with -0.77% (-0.99, -0.54;  $P < 0.001$ );

however, the results for FBS and PPG outcomes remained unchanged (Table 2).

### Lipid profile

A pooled data analysis showed no significant improvement

Table 1. Study attributes that were part of the meta-analysis

Study, year	Country	Study design	Participants	Age (mean) or range (year)	Intervention	Control	Duration	Outcomes
Khan et al. 1998	India	RCT	DM	N/A	Freeze-dried leaves of <i>C. grandis</i> tablets (n=61)	Placebo tablets (n=61)	42 days	FBS, PPG
Kuriya, et al. 2008	India	DRCT	DM type 2	47.05±6.0	<i>C. grandis</i> extract 500 mg/d (n=30)	Maltodextrin capsules 500 mg/d (n=29)	90 days	FBS, PPG, HbA1C, LDL, HDL, TC, TG
Munasinghe, et al. 2011	Sri Lanka	DRCT	DM type 2	35±11.5	<i>C. grandis</i> leaves 20 g/d (n=61)	Placebo 20 g/d (n=61)	1 day	FBS, PPG
Leeprakon, et al. 2017	Thailand	RCT	DM type 2	46-70	<i>C. grandis</i> 500 mg/d (n=28)	Placebo (n=28)	60 days	FBS, HbA1C
Wasana, et al. 2021	Sri Lanka	DRCT	DM type 2	48.64±7.09	<i>C. grandis</i> 500 mg/d (n=79)	Corn starch 500 mg/d (n=79)	90 days	FBS, HbA1C, LDL, HDL, TC, TG, renal function test, liver function test
Junaid, et al. 2020	India	RCT	DM type 2	30-60	<i>C. grandis</i> 360 g/d (n=15)	Barley flour (n=15)	30 days	FBS, HbA1C, PPG
Pickering, et al. 2023	Australia	DRCT	Pre-DM	27-73	<i>C. grandis</i> extract 500 mg/d (n=25)	Maltodextrin 500 mg (n=23)	48 days	FBS, HbA1C, PPG, LDL, HDL, TC, TG, renal function test, liver function test

Abbreviations: RCT, randomized controlled trial; DRCT, double blind randomized controlled trial; DM, diabetes mellitus; FBS, fasting blood sugar; PPG, postprandial glucose; HbA1C, Hemoglobin A1C; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TC, total cholesterol; TG, triglyceride; N/A, not available.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
1) Khan et al. 1998	+	+	?	+	+	?	?
2) Kuriya, et al. 2008	?	?	?	+	+	+	?
3) Munasinghe, et al. 2011	+	?	+	+	+	+	?
4) Leeprakon, et al. 2017	+	+	?	+	+	+	?
5) Junaid, et al. 2020	?	-	-	?	+	+	?
6) Wasana, et al. 2021	+	+	+	+	+	+	?
7) Pickering, et al. 2023	+	+	+	+	+	+	?

**Figure 2.** Reporting risk of bias assessment of each defining element of the recruited studies. +: low risk; -: high risk; ?: unclear.

in LDL (SMD -0.17 mg/dL; 95% CI: -0.41, 0.07;  $P=0.16$ ), HDL (SMD 0.10 mg/dL; 95% CI: -0.23, 0.43;  $P=0.56$ ), or TC (SMD -0.11 mg/dL; 95% CI: -0.35, 0.13;  $P=0.38$ ) after *C. grandis* treatment. However, *C. grandis* significantly decreased triglyceride levels (SMD -0.46 mg/dL; 95% CI: -0.74, -0.18;  $P=0.001$ ). There was no significant heterogeneity in these outcomes ( $I^2 < 50.0\%$ ). After changing the model from a random effect model to a fixed effect model in a sensitivity analysis, all of the outcomes' conclusions remained unchanged (Table 2).

**Table 2.** The main analysis outcomes and sensitivity analysis

Outcomes	Main analysis N; SMD [95%CI]; $I^2$	Sensitivity analysis N; SMD [95%CI]; $I^2$	References
<b>Blood glucose</b>			
FBS	299; -1.99 [-2.95, -1.04]; 95.0%*	296; -1.15 [-1.34, -0.97]; 95.0%*	(22-28)
HbA1C	176; -0.71 [-1.44, 0.01]; 89.0%	174; -0.77 [-0.99, -0.54]; 89.0%*	(23,25-28)
1-Hour PPG	162; -0.99 [-1.79, -0.19]; 90.0%*	160; -0.51 [-0.74, -0.29]; 90.0%*	(22,24,26,28)
2-Hour PPG	177; -0.69 [-1.16, -0.21]; 78.0%*	174; -0.72 [-0.93, -0.50]; 78.0%*	(22-24,28)
<b>Lipid profile</b>			
LDL	133; -0.17 [-0.41, 0.07]; 0.0%	132; -0.17 [-0.41, 0.07]; 0.0%	(23,27,28)
HDL	133; 0.10 [-0.23, 0.43]; 38.0%	132; 0.07 [-0.17, 0.32]; 38.0%	(23,27,28)
Total cholesterol	133; -0.11 [-0.35, 0.13]; 0.0%	132; -0.11 [-0.35, 0.13]; 0.0%	(23,27,28)
Triglyceride	133; -0.46 [-0.74, -0.18]; 18.0%*	132; -0.47 [-0.72, -0.23]; 18.0%	(23,27,28)

Abbreviations: FBS, fasting blood sugar; PPG: postprandial glucose; HbA1C, Hemoglobin A1C; LDL, low-density lipoprotein; HDL, high-density lipoprotein; SMD, standardized mean difference.

\*  $P \leq 0.05$  compared to the control group.

**Adverse event**

Munasinghe et al (24) reported that the adverse events of *C. grandis* administration were nausea (1.7%), headache (5%), and drowsiness (29%). A study in Thailand (25) found that the adverse events of *C. grandis* were dizziness (3.57%), insomnia (3.57%), and rash (1.78%). Two studies assessed other safety profiles using renal and liver function test parameters (27,28). The meta-analysis showed that *C. grandis* significantly altered AST and ALT levels, but not renal function tests (Table 3).

**Subgroup analysis**

Subgroup analysis by study design, *C. grandis* extraction method, and treatment duration revealed that the double-blinded RCTs (DRCTs) improved FBS and 1-hour PPG, and both RCTs and DRCTs significantly decreased 2-hour PPG. *C. grandis* extraction significantly reduced FBS and 2-hour PPG. Treatment duration longer than or equal to 90 days improved FBS, 1-hour PPG, and 2-hour PPG (Table 4).

**Publication bias**

To evaluate publication bias in the meta-analysis, a funnel plot was employed (Figure 3). The funnel plot was symmetrical, suggesting no significant publication bias.

**Discussion**

A comprehensive review and meta-analysis was conducted to ascertain the efficacy of *C. grandis* in reducing FBS, PPG, and triglyceride. Although the meta-analysis comprised seven studies, the sample size, research methodologies, and outcomes were not all the same. Based on an evaluation of the studies' quality using the Cochrane Risk of Bias Tool for Randomized Controlled Trials (21), it was discovered that the majority of the studies had a high risk of bias. This study demonstrated a statistically significant reduction in post-FBS, HbA1c, and post-meal blood sugar at 60 minutes. Blood glucose levels after eating at 60 and

**Table 3.** Renal and liver function test parameters of *Coccinia grandis* vs comparators


Outcomes	Main analysis N; SMD [95%CI]; I <sup>2</sup>	Sensitivity analysis N; SMD [95%CI]; I <sup>2</sup>	References
Renal function			
Serum creatinine	104; 0.26 [-0.04, 0.55]; 7.0%	102; 0.26 [-0.01, 0.54]; 7.0%	(27,28)
GFR	25; 0.11 [-0.46, 0.68]; N/A	23; 0.11 [-0.46, 0.68]; N/A	(28)
Liver function test			
AST	104; 0.35 [0.08, 0.63]; 0.0%	102; 0.35 [0.08, 0.63]; 0.0%	(27,28)
ALT	104; 0.51 [-0.15, 1.17]; 75.0%	102; 0.37 [0.09, 0.64]; 75%	(27,28)
GGT	104; -0.00 [-0.66, 0.65]; 76.0%	102; 0.13 [-0.14, 0.41]; 76.0%	(27,28)
ALP	104; -0.22 [-0.50, 0.05]; 0.0%	102; -0.22 [-0.50, 0.05]; 0.0%	(27,28)

Abbreviations: GFR, glomerular filtration rate; AST, aspartate transaminase; ALT, alanine transaminase; GGT, gamma-glutamyl transferase; ALP, alkaline phosphatase; SMD, standardized man difference; N/A, not available

120 minutes were also statistically significantly reduced.

*Coccinia grandis* is a plant species that possesses a wide range of bioactive phytochemicals in its leaves and aerial parts. Rutin, quercetin, and kaempferol are present in the ethanolic extract and rutin, kaempferol, and

kappacontane in the methanolic extract (29,30). Moreover, the fruit extract in question is made up of several different substances, such as undecanol,  $\beta$ -sitosterol acetate, tocopherol, stigmatosterol, ethisteron, campoesterol, and campesterol (31). It is worth mentioning that flavonoids



**Figure 3.** Funnel plots detailing publication bias. Abbreviations: FBS, fasting blood glucose; HbA1C, hemoglobin A1C; PPG, postprandial glucose; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

**Table 4.** Analyzing randomized controlled trial (RCT) subgroups to assess the impact of *Coccinia grandis* on clinical results

Outcomes	No. of trials	SMD	95% CI	I <sup>2</sup> (%)	P <sup>a</sup>	P <sup>b</sup>
<b>FBS</b>						
Study design						
RCT	3	-4.73	-7.82, -1.64	97.0	0.003	<0.001
DRCT	4	-0.93	-1.15, -0.71*	95.0	<0.001	<0.001
Extraction						
Non	3	-2.58	-4.34, -0.82*	97.0	0.004	<0.001
Extracted	4	-1.78	-2.99, -0.57*	95.0	0.004	<0.001
Duration						
<90 days	5	-2.29	-3.66, -0.93*	96.0	0.001	<0.001
≥90 days	2	-1.81	-2.12, -1.49*	1.0	<0.001	0.32
<b>HbA1C</b>						
Study design						
RCT	2	-1.22	-3.13, 0.70	93.0	0.21	<0.001
DRCT	3	-0.41	-1.19, 0.37	88.0	0.30	<0.001
Extraction						
Non	1	-0.24	-0.95, 0.48	N/A	0.52	N/A
Extracted	4	-0.82	-1.68, 0.03	91.0	0.06	<0.001
Duration						
<90 days	3	-0.76	-2.18, 0.66	93.0	0.29	<0.001
≥90 days	2	-0.66	-1.53, 0.21	88.0	0.14	<0.001
<b>1-hr PPG</b>						
Study design						
RCT	2	-2.22	-5.73, 1.30	96.0	0.22	<0.001
DRCT	2	-0.35	-0.65, -0.05*	0.0	0.02	0.63
Extraction						
Non	3	-1.34	-2.44, -0.25*	93.0	0.02	<0.001
Extracted	1	-0.23	-0.80, 0.33	N/A	0.42	N/A
<b>2-hr PPG</b>						
Study design						
RCT	1	-1.27	-1.66, -0.88*	N/A	<0.001	N/A
DRCT	3	-0.46	-0.72, -0.20*	0.0	<0.001	0.38
Extraction						
Non	2	-0.83	-1.69, 0.02	90.0	0.06	<0.001
Extracted	2	-0.53	-1.04, -0.02*	41.0	0.04	0.19
Duration						
<90 days	3	-0.66	-1.30, -0.02*	85.0	0.04	<0.001
≥90 days	1	-0.78	-1.31, -0.25*	N/A	0.004	N/A
<b>LDL</b>						
Duration						
<90 days	1	-0.32	-0.90, 0.25	N/A	0.26	N/A
≥90 days	2	-0.16	-0.48, 0.16	24.0	0.33	0.25
<b>HDL</b>						
Duration						
<90 days	1	-0.10	-0.66, 0.47	N/A	0.73	N/A
≥90 days	2	0.19	-0.31, 0.69	64.0%	0.45	0.10
<b>Total cholesterol</b>						
Duration						
<90 days	1	-0.02	-0.59, 0.54	N/A	0.93	N/A
≥90 days	2	-0.12	-0.39, 0.15	2.0%	0.37	0.31
<b>Triglyceride</b>						
Duration						
<90 days	1	-0.51	-1.09, 0.06	N/A	0.08	N/A
≥90 days	2	-0.40	-0.86, 0.06	59.0%	0.09	0.12

Abbreviations: FBS, fasting blood sugar; DRCT, double-blinded randomized controlled trials; SMD, standardized mean difference; CI, confidence interval; PPG, post prandial glucose; LDL, low-density lipoprotein; HDL, high-density lipoprotein; N/A, not applicable.

<sup>a</sup> P value of effect size; <sup>b</sup> P value of heterogeneity; \*P ≤ 0.05 compared to the control group.

constitute the predominant phenolic group in *C. grandis* and have been recognized for their potential antidiabetic properties (32,33).

*Coccinia grandis* may reduce hyperglycemia by increasing  $\beta$ -cell proliferation, stimulating insulin secretion, reducing apoptosis, and controlling liver glucose metabolism (34). The most prevalent flavonoid in *C. grandis*, quercetin, has been demonstrated to have antidiabetic effects via a variety of pathways. Quercetin reduced the absorption of glucose and fructose in human intestinal Caco-2 cells by 75% and inhibited the glucose transporter 2 (GLUT2) (35). Additionally, quercetin inhibits  $\alpha$ -amylase and  $\alpha$ -glucosidase, two hydrolytic enzymes that convert carbs into simple sugars. This can improve blood glucose regulation after a meal and slow down the digestion of carbohydrates (36,37). Quercetin protects pancreatic  $\beta$ -cells from oxidative stress, which is implicated in  $\beta$ -cell damage and diabetes. Quercetin has been shown to protect pancreatic  $\beta$ -cells from damage in streptozotocin (STZ)-induced diabetic rats by directly reducing nitric oxide and malondialdehyde levels and indirectly increasing antioxidant enzyme activity. It also increased insulin secretion in these rats (38). When *Vaccinium vitis-idaea* produced quercetin glycosides, which were given to STZ-induced diabetic rats, the 5' adenosine monophosphate-activated protein kinase (AMPK) pathway was seen to be activated (39). In diabetic rats, quercetin increased the expression of glucose transporter 4 (GLUT4). This increase in GLUT4 expression led to increased glucose absorption into the muscle cells (40).

The inhibition of carbohydrate-digesting enzymes within the gastrointestinal tract presents a potentially effective treatment strategy for managing diabetes mellitus, as it has the potential to mitigate postprandial hyperglycemia. Compounds possessing enzyme inhibitory activity have been observed to impede the process of carbohydrate digestion, extending the overall duration of carbohydrate breakdown and resulting in a decrease in the amount of glucose absorption (41). The extract derived from the leaves of *C. grandis* has demonstrated significant inhibitory effects on  $\alpha$ -amylase and  $\alpha$ -glucosidase enzymes. For instance, the methanolic (50% v/v) extract obtained from the leaves of *C. grandis* was shown to inhibit the enzymatic activity of  $\alpha$ -amylase (42). In a study conducted by Mohammed et al (43), the ethanolic extract of *C. grandis* leaves exhibited inhibitory action against  $\alpha$ -amylase. The IC<sub>50</sub> value for this inhibition was determined to be  $78.47 \pm 0.18 \mu\text{g/mL}$ . As reported by Pulbutr et al (44), the  $\alpha$ -amylase activity of *C. grandis* was found to be strongly inhibited by an aqueous extract obtained from the leaves and stems. The IC<sub>50</sub> values for the extract were determined to be  $8.09 \pm 0.72 \text{ mg/mL}$  and  $8.06 \pm 1.27 \text{ mg/mL}$  for the leaves and stems, respectively. Additionally, it demonstrated inhibitory effects on  $\alpha$ -glucosidase activity,

with IC<sub>50</sub> values of  $77.66 \pm 9.16 \mu\text{g/mL}$  and  $0.75 \pm 0.11 \text{ mg/mL}$  for the two corresponding compounds, respectively.

*Coccinia grandis* significantly reduced the TG levels in a meta-analysis but had no effect on LDL, HDL, or TC. This is interesting because diabetes and dyslipidemia are closely related. The lipid profile of rats is compromised due to the presence of hyperglycemia when they acquire diabetes, leading to disturbances in lipoprotein metabolism. As a result, there is an elevation in the levels of TG, TC, very low-density lipoprotein (VLDL), and LDL, accompanied by a reduction in HDL levels. This can be attributed to the excessive release of adipose tissue fat (45).

Several studies have demonstrated that administering a *C. grandis* extract to diabetic rats enhances their lipid profiles. In diabetic mice caused by alloxan, Manjula and Ragavan (46) reported reductions in blood glucose, TC, TG, VLDL, and LDL upon the administration of an aqueous leaf extract of *C. grandis*. Additionally, Attanayake et al (47) demonstrated that STZ-induced diabetic rats that received oral delivery of *C. grandis* leaf extract in aqueous form for a duration of 30 days exhibited decreased levels of TC, LDL-C, VLDL-C, and TG, while HDL-C levels were elevated.

The reduction in TG observed in the *C. grandis* group in the meta-analysis is consistent with these findings. Potential mechanism of action of *C. grandis* might be reduction of cholesterol by enhancing islet beta cell activity and insulin resistance.

Several studies have investigated the association between reductions in FBS and PPG and the relative risk reduction of CVD. A recent meta-analysis showed that blood glucose control could reduce major adverse cardiovascular events (48). According to Chiasson et al (49), a decrease in PPG with the  $\alpha$ -glucosidase inhibitor acarbose for three years was linked to a 49% relative risk reduction in the development of CVDs in patients with impaired glucose tolerance. Nevertheless, the longest treatment period in the studies that made up the meta-analysis was 90 days, which might not be sufficient to produce the previously indicated clinical advantages. Thus, more extensive research is required to assess the clinical advantages and risk mitigation of *C. grandis* in CVD. Although no significant adverse events were linked to *C. grandis* in this systematic review and meta-analysis (24), we looked into the uncommon occurrence of side effects pertaining to hepatic and renal functions. According to this study, when participants started using *C. grandis*, their levels of aspartate aminotransferase and alanine aminotransferase dramatically increased (27,28). The most frequently observed adverse effects involved the central nervous system and gastrointestinal system, but no severe adverse effects were reported (24,27,28).

The studies that were included had excellent methodological standards. It should be highlighted that there were several limitations. Initially, the majority of



trials had a small sample size, which limited statistical power. However, this was mitigated by using appropriate statistical tests for pooled data. Furthermore, although most participants had diabetes, none had abnormal lipid profile. This may have confounded the assessment of the sole effect of *C. grandis* on lipid profiles. Finally, most trials have assessed the factors for a short term.

### Conclusion

The existing evidence suggests that various forms of *C. grandis* promote FBS and PPG reduction and improve triglyceride levels. However, the sample sizes of the included trials were mostly small. Large-scale RCTs and long-term evaluation of the effects of *C. grandis* on HbA1c levels and lipid profiles are warranted.

### Acknowledgments

We would like to thank Professor Adrian Roderick Plant for language assistance.

### Authors' contributions

**Conceptualization:** Wiraphol Phimarn, Chatmanee Taengthonglang and Bunleu Sungthong.

**Data collection:** Wiraphol Phimarn, Chatmanee Taengthonglang, and Bunleu Sungthong.

**Formal analysis:** Wiraphol Phimarn and Chatmanee Taengthonglang.

**Funding acquisition:** Wiraphol Phimarn.

**Investigation:** Wiraphol Phimarn and Chatmanee Taengthonglang.

**Methodology:** Wiraphol Phimarn, Chatmanee Taengthonglang and Bunleu Sungthong.

**Project administration:** Wiraphol Phimarn.

**Resources:** Wiraphol Phimarn and Chatmanee Taengthonglang.

**Software:** Wiraphol Phimarn and Chatmanee Taengthonglang.

**Supervision:** Bunleu Sungthong.

**Visualization:** Wiraphol Phimarn, Bunleu Sungthong.

**Writing original draft:** Wiraphol Phimarn.

**Writing review & editing:** Wiraphol Phimarn, Chatmanee Taengthonglang, and Bunleu Sungthong.

### Conflict of interests

The authors declare that they have no conflict of interest.

### Ethical considerations

Ethical issues (including plagiarism, data fabrication, double publication etc.) have been completely observed by the authors. We performed the protocol in accordance with PRISMA guideline.

### Funding

This research project was financially supported by Mahasarakham University (Grant No. 2567).

### References

- de Magalhães Cunha C, Costa PR, de Oliveira LPM, de Oliveira Queiroz VA, Pitangueira JC, Oliveira AM. Dietary patterns and cardiometabolic risk factors among adolescents: systematic review and meta-analysis. *Br J Nutr*. 2018;119(8):859-79. doi: 10.1017/s0007114518000533.
- Rao GH. Prevention or reversal of cardiometabolic diseases. *J Clin Prev Cardiol*. 2018;7(1):22-8. doi: 10.4103/jcpc.jcpc\_41\_17.
- Danaei G, Lu Y, Singh GM, Carnahan E, Stevens GA, Cowan MJ, et al. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. *Lancet Diabetes Endocrinol*. 2014;2(8):634-47. doi: 10.1016/s2213-8587(14)70102-0.
- McQueen RB, Ghushchyan V, Olufade T, Sheehan JJ, Nair KV, Saseen JJ. Incremental increases in economic burden parallels cardiometabolic risk factors in the US. *Diabetes Metab Syndr Obes*. 2016;9:233-41. doi: 10.2147/dms.s106809.
- Phimarn W, Wichaiyo K, Silpsavikul K, Sungthong B, Saramunee K. A meta-analysis of efficacy of *Morus alba* Linn. to improve blood glucose and lipid profile. *Eur J Nutr*. 2017;56(4):1509-21. doi: 10.1007/s00394-016-1197-x.
- Tian L, Liu Y, Qin Y, Long S, Xu Y, Fu M. Association of the low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio and concentrations of plasma lipids with high-density lipoprotein subclass distribution in the Chinese population. *Lipids Health Dis*. 2010;9:69. doi: 10.1186/1476-511x-9-69.
- Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JE, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J*. 2020;41(24):2313-30. doi: 10.1093/eurheartj/ehz962.
- Davidson JA, Parkin CG. Is hyperglycemia a causal factor in cardiovascular disease? Does proving this relationship really matter? *Yes*. *Diabetes Care*. 2009;32(Suppl 2):S331-3. doi: 10.2337/dc09-S333.
- Wu T, Fu J, Yang Y, Zhang L, Han J. The effects of phytosterols/stanols on blood lipid profiles: a systematic review with meta-analysis. *Asia Pac J Clin Nutr*. 2009;18(2):179-86.
- McGillcuddy FC, Roche HM. Nutritional status, genetic susceptibility, and insulin resistance--important precedents to atherosclerosis. *Mol Nutr Food Res*. 2012;56(7):1173-84. doi: 10.1002/mnfr.201100785.
- Schubert CM, Rogers NL, Remsberg KE, Sun SS, Chumlea WC, Demerath EW, et al. Lipids, lipoproteins, lifestyle, adiposity and fat-free mass during middle age: the Fels Longitudinal Study. *Int J Obes (Lond)*. 2006;30(2):251-60. doi: 10.1038/sj.ijo.0803129.
- Lari A, Sohoulis MH, Fatahi S, Cerqueira HS, Santos HO, Pourrajab B, et al. The effects of the Dietary Approaches to Stop Hypertension (DASH) diet on metabolic risk factors in patients with chronic disease: a systematic review and meta-analysis of randomized controlled trials. *Nutr Metab Cardiovasc Dis*. 2021;31(10):2766-78. doi: 10.1016/j.numecd.2021.05.030.
- O'Keefe JH, Gheewala NM, O'Keefe JO. Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. *J Am Coll Cardiol*. 2008;51(3):249-55. doi: 10.1016/j.jacc.2007.10.016.
- Attanayake AP, Jayatilaka KA, Mudduwa LK. Anti-diabetic potential of ivy gourd (*Coccinia grandis*, family:

- Cucurbitaceae) grown in Sri Lanka: a review. *J Pharmacogn Phytochem.* 2016;5(6):286-9.
15. Modak M, Dixit P, Londhe J, Ghaskadbi S, Devasagayam TP. Indian herbs and herbal drugs used for the treatment of diabetes. *J Clin Biochem Nutr.* 2007;40(3):163-73. doi: 10.3164/jcbs.40.163.
  16. Mukherjee PK, Nema NK, Maity N, Sarkar BK. Phytochemical and therapeutic potential of cucumber. *Fitoterapia.* 2013;84:227-36. doi: 10.1016/j.fitote.2012.10.003.
  17. Attanayake AP, Jayatilaka KA, Pathirana C, Mudduwa LK. Antihyperglycemic activity of *Coccinia grandis* (L.) Voigt in streptozotocin induced diabetic rats. *Indian J Tradit Knowl.* 2015;14(3):376-81.
  18. Krishnakumari S, Bhuvaneshwari P, Rajeswari P. Ameliorative potential of *Coccinia grandis* extract on serum and liver marker enzymes and lipid profile in streptozotocin induced diabetic rats. *Anc Sci Life.* 2011;31(1):26-30.
  19. Attanayake AP, Jayatilaka KA, Pathirana C, Mudduwa LK. Efficacy and toxicological evaluation of *Coccinia grandis* (Cucurbitaceae) extract in male Wistar rats. *Asian Pac J Trop Dis.* 2013;3(6):460-6. doi: 10.1016/s2222-1808(13)60101-2.
  20. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *J Clin Epidemiol.* 2021;134:178-89. doi: 10.1016/j.jclinepi.2021.03.001.
  21. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ.* 2011;343:d5928. doi: 10.1136/bmj.d5928.
  22. Khan AK, S AK, Mahtab H. Treatment of diabetes mellitus with *Coccinia indica*. *Br Med J.* 1980;280(6220):1044. doi: 10.1136/bmj.280.6220.1044.
  23. Kuriyan R, Rajendran R, Bantwal G, Kurpad AV. Effect of supplementation of *Coccinia cordifolia* extract on newly detected diabetic patients. *Diabetes Care.* 2008;31(2):216-20. doi: 10.2337/dc07-1591.
  24. Munasinghe MA, Abeysena C, Yaddehige IS, Vidanapathirana T, Piyumal KP. Blood sugar lowering effect of *Coccinia grandis* (L.) J. Voigt: path for a new drug for diabetes mellitus. *Exp Diabetes Res.* 2011;2011:978762. doi: 10.1155/2011/978762.
  25. Leeprakon A, Khomeklang P, Sompang W, Pongpladisai A, Thorajak P. No title effect of *Coccinia grandis* (L.) Voigt on blood sugar levels in pre-diabetes mellitus of non-insulin dependent type. *Koch Cha Sarn J Sci.* 2017;39(1):110-20.
  26. Junaid M, Singh B, Vats S, Thapliyal S, Thapliyal S. Anti-hyperglycemic effect of kundru (*Coccinia indica*) on patients of diabetes mellitus type-2. *Int J Ayurveda Pharma Res.* 2020;8(11):29-35. doi: 10.47070/ijapr.v8i11.1681.
  27. Wasana KGP, Attanayake AP, Weerarathna TP, Jayatilaka K. Efficacy and safety of a herbal drug of *Coccinia grandis* (Linn.) Voigt in patients with type 2 diabetes mellitus: a double-blind randomized placebo controlled clinical trial. *Phytomedicine.* 2021;81:153431. doi: 10.1016/j.phymed.2020.153431.
  28. Pickering E, Steels E, Castaneda R, Steadman KJ. Effect of *Coccinia grandis* (Linn.) Voigt extract on glucose metabolism markers in a prediabetic population: a double-blind randomised clinical trial. *Phytomed Plus.* 2023;3(4):100487. doi: 10.1016/j.phyplu.2023.100487.
  29. Deokate UA, Khadabadi SS. Pharmacology and phytochemistry of *Coccinia indica*. *J Pharmacognosy Phytother.* 2011;3(11):155-9. doi: 10.5897/jpp11.005.
  30. Al-Madhagy SA, Mostafa NM, Youssef FS, Awad GE, Eldahshan OA, Singab AN. Metabolic profiling of a polyphenolic-rich fraction of *Coccinia grandis* leaves using LC-ESI-MS/MS and in vivo validation of its antimicrobial and wound healing activities. *Food Funct.* 2019;10(10):6267-75. doi: 10.1039/c9fo01532a.
  31. Kondhare D, Lade H. Phytochemical profile, aldose reductase inhibitory, and antioxidant activities of Indian traditional medicinal *Coccinia grandis* (L.) fruit extract. *3 Biotech.* 2017;7(6):378. doi: 10.1007/s13205-017-1013-1.
  32. Patra JC, Chua BH. Artificial neural network-based drug design for diabetes mellitus using flavonoids. *J Comput Chem.* 2011;32(4):555-67. doi: 10.1002/jcc.21641.
  33. Mukhopadhyay P, Prajapati AK. Quercetin in anti-diabetic research and strategies for improved quercetin bioavailability using polymer-based carriers – a review. *RSC Adv.* 2015;5(118):97547-62. doi: 10.1039/c5ra18896b.
  34. Al-Ishaq RK, Abotaleb M, Kubatka P, Kajo K, Büsselberg D. Flavonoids and their anti-diabetic effects: cellular mechanisms and effects to improve blood sugar levels. *Biomolecules.* 2019;9(9):430. doi: 10.3390/biom9090430.
  35. Kwon O, Eck P, Chen S, Corpe CP, Lee JH, Kruhlak M, et al. Inhibition of the intestinal glucose transporter GLUT2 by flavonoids. *FASEB J.* 2007;21(2):366-77. doi: 10.1096/fj.06-6620com.
  36. Limanto A, Simamora A, Santoso AW, Timotius KH. Antioxidant,  $\alpha$ -glucosidase inhibitory activity and molecular docking study of gallic acid, quercetin and rutin: a comparative study. *Mol Cell Biomed Sci.* 2019 Sep 1;3(2):67-74.
  37. Kumar S, Kumar V, Prakash O. Enzymes inhibition and antidiabetic effect of isolated constituents from *Dillenia indica*. *Biomed Res Int.* 2013;2013:382063. doi: 10.1155/2013/382063.
  38. Adewole SO, Caxton-Martins EA, Ojewole JA. Protective effect of quercetin on the morphology of pancreatic beta-cells of streptozotocin-treated diabetic rats. *Afr J Tradit Complement Altern Med.* 2006;4(1):64-74. doi: 10.4314/ajtcam.v4i1.31196.
  39. Eid HM, Martineau LC, Saleem A, Muhammad A, Vallerand D, Benhaddou-Andaloussi A, et al. Stimulation of AMP-activated protein kinase and enhancement of basal glucose uptake in muscle cells by quercetin and quercetin glycosides, active principles of the antidiabetic medicinal plant *Vaccinium vitis-idaea*. *Mol Nutr Food Res.* 2010;54(7):991-1003. doi: 10.1002/mnfr.200900218.
  40. Alam MM, Meerza D, Naseem I. Protective effect of quercetin on hyperglycemia, oxidative stress and DNA damage in alloxan induced type 2 diabetic mice. *Life Sci.* 2014;109(1):8-14. doi: 10.1016/j.lfs.2014.06.005.
  41. Benrahou K, Naceiri Mrabti H, Bouyahya A, Daoudi NE, Bnouham M, Mezzour H, et al. Inhibition of  $\alpha$ -amylase,  $\alpha$ -glucosidase, and lipase, intestinal glucose absorption, and antidiabetic properties by extracts of *Erodium guttatum*. *Evid Based Complement Alternat Med.* 2022;2022:5868682. doi: 10.1155/2022/5868682.
  42. Jaiboon V, Boonyanuphap J, Suwansri S, Ratanatraiwong

- P, Hansawasdi C. Alpha amylase inhibition and roasting time of local vegetables and herbs prepared for diabetes risk reduction chili paste. *Asian Journal of Food and Agro-Industry*. 2010;3(1):1-12.
43. Mohammed SI, Chopda MZ, Patil RH, Vishwakarma KS, Maheshwari VL. In vivo antidiabetic and antioxidant activities of *Coccinia grandis* leaf extract against streptozotocin induced diabetes in experimental rats. *Asian Pac J Trop Dis*. 2016;6(4):298-304. doi: 10.1016/s2222-1808(15)61034-9.
44. Pulbutr P, Saweeram N, Ittisan T, Intrama H, Jaruchotikamol A, Cushnie B. In vitro  $\alpha$ -amylase and  $\alpha$ -glucosidase inhibitory activities of *Coccinia grandis* aqueous leaf and stem extracts. *J Biol Sci*. 2017;17(2):61-8.
45. Bhat BM, Raghuvver CV, D'Souza V, Manjrekar PA. Antidiabetic and hypolipidemic effect of *Salacia oblonga* in streptozotocin induced diabetic rats. *J Clin Diagn Res*. 2012;6(10):1685-7. doi: 10.7860/jcdr/2012/4728.2644.
46. Manjula S, Ragavan B. Hypoglycemic and hypolipidemic effect of *Coccinia indica* Wight & Arn in alloxan induced diabetic rats. *Anc Sci Life*. 2007;27(2):34-7.
47. Attanayake AP, Jayatilaka K, Mudduwa LK, Pathirana C.  $\beta$ -cell regenerative potential of selected herbal extracts in alloxan induced diabetic rats. *Curr Drug Discov Technol*. 2019;16(3):278-84. doi: 10.2174/1570163815666180418153024.
48. Hasebe M, Yoshiji S, Keidai Y, Minamino H, Murakami T, Tanaka D, et al. Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials. *Cardiovasc Diabetol*. 2023;22(1):62. doi: 10.1186/s12933-023-01773-z.
49. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. *JAMA*. 2003;290(4):486-94. doi: 10.1001/jama.290.4.486.